Overexpression of this gene in bladder cancer tumor xenografts has been shown to confer tolerance to gemcitabine67 suggesting that NAFLD patients could have increased liver toxicity when treated with gemcitabine due to a decreased abundance of MAT1A. Here, MAT1A is linked to metabolic dysfunction-associated steatotic liver disease.